Table 3 Change in HbA1c levels over 18 months after initiation of second-line treatment
Second-line treatment | 6 months | 12 months | 18 months | ||||||
|---|---|---|---|---|---|---|---|---|---|
N (%) | Mean change in HbA1c (SE)* | N (%) | Mean change in HbA1c (SE)* | N (%) | Mean change in HbA1c (SE)* | ||||
% | mmol/mol | % | mmol/mol | % | mmol/mol | ||||
MET + SU | 2257 (50.38) | −1.33 (0.04) | −14.5 (0.4) | 1571 (51.01) | −1.30 (0.04) | −14.2 (0.4) | 907 (51.68) | −1.21 (0.05) | −13.2 (0.5) |
MET + DPP-4i | 1486 (33.17) | −1.11 (0.04) | −12.1 (0.4) | 1044 (33.90) | −1.12 (0.05) | −12.2 (0.5) | 572 (32.59) | −1.23 (0.06) | −13.4 (0.7) |
MET + SGLT-2i | 225 (5.02) | −1.26 (0.08) | −13.8 (0.9) | 156 (5.06) | −1.32 (0.10) | −14.4 (1.1) | 90 (5.13) | −1.46 (0.13) | −16.0 (1.4) |
Other† | 512 (11.43) | −1.03 (0.06) | −11.3 (0.7) | 309 (10.03) | −1.20 (0.08) | −13.1 (0.9) | 186 (10.60) | −1.18 (0.10) | −12.9 (1.1) |
Overall | 4480 | −1.23 (0.03) | −13.4 (0.3) | 3080 | −1.24 (0.04) | −13.6 (0.4) | 1755 | −1.23 (0.05) | −13.4 (0.5) |